选择语言
免费注册
关注公众号
微信客服
收藏产品

Biotinylated Human CD20 Full Length Protein (VLP)

COADS MS
DS
用户评价
货号-规格
价格
Qty.
CD0-H82P3-20ug
¥7875.00
CD0-H82P3-100ug
¥15750.00
CD0-H82P3-500ug (250ug X 2)
询价
合计0件 产品金额¥ 0
新品建议
增项建议

产品详情

  • 分子别名（Synonym）

    MS4A1, CD20, MS4A-1

  • 表达区间及表达系统（Source）

    Biotinylated Human CD20 Full Length Protein (VLP) (CD0-H82P3) is expressed from human 293 cells (HEK293). It contains AA Met 1 - Pro 297 (Accession # P11836-1).

    Predicted N-terminus: Met 1

  • 蛋白结构（Molecular Characterization）

    Virus-like particles(VLPs) are formed by self-assembly of capsid proteins from viruses. Membrane Proteins can be constituted in-situ with VLPs produced from HEK293 cell cultures. These VLPs concentrate conformationally intact membrane proteins directly on the cell surface and produce soluble, high-concentration proteins perfect for immunization and antibody screening.

    The VLPs provide the display of properly folded membrane proteins in their native cellular membrane in a compact size of 100~300 nm diameter (similar to the size of most viruses) making it optimal targets for dendritic cells in vivo and surface attachment for phage display.

  • 标记（Labeling）

    The VLP is biotinylated with propriety technology.

  • 蛋白标记度（Protein Ratio）

    Passed as determined by the HABA assay / binding ELISA.

  • 制剂（Formulation）

    The VLPs are highly immunogenic, so the immunization strategy should be optimized (antigen dose, regimen and adjuvant).

    Supplied as 0.2 μm filtered solution in PBS, Arginine, pH7.4 with trehalose as protectant.

    Contact us for customized product form or formulation.

  • 运输（Shipping）

    This product is supplied and shipped with dry ice, please inquire the shipping cost.

  • 存储（Storage）

    Please avoid repeated freeze-thaw cycles.

    This product is stable after storage at:

    1. The product MUST be stored at -70°C or lower upon receipt;
    2. -70°C for 12 months under sterile conditions.

  • 质量管理控制体系（QMS）

    1. 质量管理体系（ISO, GMP）
    2. 质量优势
    3. 质控流程
  • *The isotype control of empty/mock VLP (Cat. No. VLP-N82P3) is sold separately and not included in protein, you can follow the link for product information.

推荐产品

数据展示

  • 活性（Bioactivity）-ELISA

    CD20 ELISA

    Immobilized Biotinylated Human CD20 Full Length Protein (VLP) (Cat. No. CD0-H82P3) at 2 μg/mL (100 μL/well) on streptavidin (Cat. No. STN-N5116) precoated (0.5 μg/well) plate can bind Rituximab biosimilar (Cat. No. CD0-M36) with a linear range of 0.2-2 ng/mL (QC tested).

    Protocol

  • CD20 ELISA

    Immobilized Biotinylated Human CD20 Full Length Protein (VLP) (Cat. No. CD0-H82P3) at 2 μg/mL (100 μL/well) on streptavidin (Cat. No. STN-N5116) precoated (0.5 μg/well) plate can bind Ofatumumab biosimilar with a linear range of 0.2-2 ng/mL (QC tested).

    Protocol

  • CD20 ELISA

    Immobilized Biotinylated Human CD20 Full Length Protein (VLP) (Cat. No. CD0-H82P3) at 2 μg/mL (100 μL/well) on streptavidin (Cat. No. STN-N5116) precoated (0.5 μg/well) plate can bind Obinutuzumab biosimilar with a linear range of 0.2-2 ng/mL (Routinely tested).

    Protocol

  • 均一性（Identity）-DLS

    CD20 DLS

    The mean peak Radius of VLP is 65-85 nm with more than 95% intensity as determined by dynamic light scattering (DLS).

用户评价
发表评论

背景介绍

B-lymphocyte antigen CD20 is also known as B-lymphocyte surface antigen B1, Leukocyte surface antigen Leu-16, Membrane-spanning 4-domains subfamily A member 1 and MS4A1, is an activated-glycosylated phosphoprotein expressed on the surface of all B-cells beginning at the pro-B phase (CD45R+, CD117+) and progressively increasing in concentration until maturity. CD20 is expressed on all stages of B cell development except the first and last; it is present from late pro-B cells through memory cells, but not on either early pro-B cells or plasma blasts and plasma cells. It is found on B-cell lymphomas, hairy cell leukemia, B-cell chronic lymphocytic leukemia, and melanoma cancer stem cells. The protein has no known natural ligand and its function is to enable optimal B-cell immune response, specifically against T-independent antigens. It is suspected that it acts as a calcium channel in the cell membrane. CD20 / MS4A1 is the target of the monoclonal antibodies (mAb) rituximab, Ibritumomab tiuxetan, and tositumomab, which are all active agents in the treatment of all B cell lymphomas and leukemias. Defects in CD20 / MS4A1 are the cause of immunodeficiency common variable type 5 (CVID5); also called antibody deficiency due to CD20 defect. CVID5 is a primary immunodeficiency characterized by antibody deficiency, hypogammaglobulinemia, recurrent bacterial infections and an inability to mount an antibody response to antigen.

前沿进展

 
药物研发进展
  • 英文全称：

    B-lymphocyte antigen CD20

  • 中文全称：

    B淋巴细胞抗原CD20

  • 种类：

  • 上市药物数量：

    33 详情

  • 临床药物数量：

    108 详情

  • 最高研发阶段：

    批准上市

联系我们
项目合作
查看更多项目
实验案例分析
查看更多案例分析
  • 产品基础信息
  • 产品详情
  • 推荐产品
  • 数据展示
  • 用户评价
  • 背景介绍